Effects of Danqi Yishen Capsule on Blood Lipid Levels and Hemorheological Indicators of Hyperlipidemia Patients

Objective: To explore the effects of Danqi Yishen Capsule (Danqi Capsule for Tonifying Kidney) on blood lipid levels and hemorheological indicators of hyperlipidemia patients. Methods: A total of 96 patients with hyperlipidemia were randomly divided into the control group and observation group of 48 cases respectively. The control group was given by simvastatin in oral administration of 10 mg half an hour after dinner, once a day, while the observation group based on the treatment of the control group, was orally given Danshen Yishen Capsule of three capsules each time, three times a day. The treatment of both groups lasted for two months. Then the comparison focused on blood lipid levels, hemorheological indicators, and adverse reactions between both groups before and after the treatment. Results: There was no significant difference in blood lipid levels and hemorheological indicators between both groups before the treatment (P > 0.05). The symptoms of both groups were significantly improved after the treatment, and the difference before and after the treatment was statistically significant (P < 0.05), and the difference between both groups was also statistically significant (P < 0.05). There was no significant difference in the incidence rate of adverse reactions between both groups (P > 0.05). Conclusion: Danqi Yishen Capsule has a significant value in clinical applications, which can optimize clinical efficacy, improve blood lipid levels and hemorheological indicators of hyperlipidemia patients, as well as reduce the probability of adverse reactions in patients.

Study on Effect of Yishen Capsule (益肾胶囊) in Preventing Recurrence of Chronic Glomerulonephritis

Objective： To observe the effect of Yishen Capsule （益肾胶囊, YSC） on preventing the recurrence of chronic glomerulonephritis （CGN） and to explore its mechanism preliminarily. Methods： CGN patients were assigned to the treated group （61 cases） and the control group （48 cases） and all of them were orally administered with 4 mg of Perindopril twice a day, but 3 capsules of YSC, thrice a day, were given additionally to patients in the treated group. The therapeutic course for both groups was 18 months. The recurrence rate of CGN at the 6th, 12th, and 18th month in the two groups was observed and compared, and the changes of 24-h urinary protein quantity and T-lymphocyte subsets before and after treatment were observed as well. Results： （1） Comparison of recurrence rate between the two groups showed insignificant difference at the 6th month, but it did show significant difference at the 12th and the 18th month, which was significantly decreased in the treated group than in the control group （P〈0.05, P〈0.01）; （2） The 24-h urinary protein quantity at the 18th month decreased significantly in both groups （P〈0.05, P〈0.01）, but in the treated group was more significant （P〈0.01）; （3） T-lymphocyte subsets showed no obvious change in the control group after treatment （P〉0.05）, while in the treated group, it showed significant increase in CD3, CD4 and CD4/CD8 （P〈0.05 or P〈0.01） and significant decrease in CD8 （P〈0.05）, and also the difference after treatment in T-lymphocyte subsets between the two groups was significant （P〈0.05 or P〈0.01）. Conclusion： YSC has marked effects in reducing the recurrence of CGN and in decreasing urinary protein, and its mechanism might be related with its function in regulating the ratio of T-lymphocyte subsets to enhance the immunity of patients.

Pharmacological mechanisms of Yishen Xingyang capsule in the treatment of oligoasthenospermia in rats

Objective:To investigate the therapeutic effects and pharmacological mechanisms of Yishen Xingyang capsule(YXC)in oligoasthenospermia(OA)rats.Methods:Forty-eight male SpragueeDawley rats were randomly divided into eight groups of six rats each:normal control(NC);model control(MC);three different positive drug(PD);and low-,medium-,and high-dose YXC groups.A rat model of OA was established by administering glucosides of Tripterygium wilfordii Hook.F(GTW).After YXC administration,penile erectile function was observed.The epididymis,blood,and testes of the rats were harvested for analysis of sperm quality,sex hormone levels,mitochondrial membrane potential,and the transforming growth factor(TGF)-b1/Smad signaling pathway.Results:Compared with that in the MC group,penile erectile function in the YXC groups and three PD groups increased(all P<.01).Moreover,sperm quality in the YXC groups and three PD groups improved(all P<.001).The levels of testosterone,follicle stimulating hormone,and luteinizing hormone in the three PD and YXC groups increased(all P<.05).The mitochondrial membrane potential in the three PD and YXC groups significantly improved(all P<.001).Furthermore,the YXC and three PD groups showed decreased TGF-b1 expression(all P<.05)compared with the MC group.The high-dose YXC group and three PD groups improved Smad2 and Smad4 expression(all P<.05).Conclusion:YXC improved penile erectile function and sperm quality in OA rats,and the underlying mechanism included increase in sex hormones,inhibition of sperm apoptosis,and regulation of the TGFb1/Smad signaling pathway.Meanwhile,this study provides a new effective drug option for the treatment of OA,which is beneficial to male reproductive health and social harmony.